Stock Events

Stock Events

Talaris Therapeutics 

$2.72
65
-$0.02-0.73% Thursday 22:00

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
113.49M
P/E Ratio
0
Dividend Yield
-
Dividend
-

Dividends

0%Dividend Yield
Oct 25
$15.12
Oct 24
$15.12
Oct 23
$15.12
Oct 23
$15.12
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A

Earnings

8NovExpected
Q1 2022
Q2 2022
Q3 2022
Q4 2022
Q1 2023
Q2 2023
Q3 2023
-0.51
-0.34
-0.17
0
Expected EPS
-0.06
Actual EPS
0

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
0Revenue
-73.89MNet Income

Analyst Ratings

$0.00Average Price Target
The highest estimate is 0.00.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow TALS. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
CRISPR Therapeutics
CRSP
Mkt Cap5.82B
CRISPR Therapeutics is a competitor because it also focuses on developing gene-based therapies, similar to Tourmaline Bio's focus on RNA-based therapies, making them direct competitors in the genetic medicine space.
Editas Medicine
EDIT
Mkt Cap276.95M
Editas Medicine operates in the genome editing field, directly competing with Tourmaline Bio in the development of genetic treatments and therapies.
Intellia Therapeutics
NTLA
Mkt Cap1.35B
Intellia Therapeutics is a leading developer of CRISPR/Cas9 gene-editing therapies, competing with Tourmaline Bio in the broader genetic medicine and therapy market.
Beam Therapeutics
BEAM
Mkt Cap2.53B
Beam Therapeutics competes with Tourmaline Bio by focusing on base editing, a novel form of gene editing, positioning itself as a competitor in the genetic therapy industry.
Alnylam Pharmaceuticals
ALNY
Mkt Cap60.25B
Alnylam Pharmaceuticals is a competitor due to its focus on RNA interference (RNAi) therapies, which overlaps with Tourmaline Bio's focus on RNA-based therapeutic approaches.
Ionis Pharmaceuticals
IONS
Mkt Cap12.03B
Ionis Pharmaceuticals competes with Tourmaline Bio by developing RNA-targeted therapies, making it a direct competitor in the RNA therapy space.
Sangamo Therapeutics
SGMO
Mkt Cap180.42M
Sangamo Therapeutics is involved in genome editing and gene therapy, competing with Tourmaline Bio in the development of genetic treatments.
Biomarin Pharmaceutical
BMRN
Mkt Cap10.29B
BioMarin Pharmaceutical focuses on developing gene therapies for rare diseases, positioning it as a competitor to Tourmaline Bio in the niche market of genetic treatments.
Voyager Therapeutics
VYGR
Mkt Cap259.04M
Voyager Therapeutics competes with Tourmaline Bio in the gene therapy space, focusing on severe neurological diseases, which may overlap with Tourmaline Bio's therapeutic areas.

About

Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune diseases. It develops medicines and therapies for the Atherosclerotic cardiovascular disease (ASCVD) and Thyroid Eye Disease (TED). The company was incorporated in 2021 and is based in New York, New York.
Show more...
CEO
Dr. Sandeep C. Kulkarni M.D.
Employees
74
Country
US
ISIN
US87410C1045

Listings

0 Comments

Share your thoughts

FAQ

What is Talaris Therapeutics stock price today?▼
The current price of TALS is $2.72 USD — it has decreased by -0.73% in the past 24 hours. Watch Talaris Therapeutics stock price performance more closely on the chart.
What is Talaris Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Talaris Therapeutics stocks are traded under the ticker TALS.
What is Talaris Therapeutics market cap?▼
Today Talaris Therapeutics has the market capitalization of 113.49M
What were Talaris Therapeutics earnings last quarter?▼
TALS earnings for the last quarter are 0 USD per share, whereas the estimation was -0.06 USD resulting in a +100% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Talaris Therapeutics revenue for the last year?▼
Talaris Therapeutics revenue for the last year amounts to 0 USD.
What is Talaris Therapeutics net income for the last year?▼
TALS net income for the last year is -73.89M USD.
Does Talaris Therapeutics pay dividends?▼
Yes, TALS dividends are paid en. The last dividend per share was 15.12 USD. As of today, Dividend Yield (FWD)% is 0%.
How many employees does Talaris Therapeutics have?▼
As of April 01, 2026, the company has 74 employees.
In which sector is Talaris Therapeutics located?▼
Talaris Therapeutics operates in the Health Care sector.
When did Talaris Therapeutics complete a stock split?▼
The last stock split for Talaris Therapeutics was on October 20, 2023 with a ratio of 1:10.
Where is Talaris Therapeutics headquartered?▼
Talaris Therapeutics is headquartered in New York, US.